Organon reports Q2 adjusted EPS of $0.85, down from $1.00, via 10-Q only amid Sun merger

Filed July 31, 2026 · Period ending July 31, 2026 · ~1 min read

Key Changes

• high

  Adjusted EPS fell to $0.85 in Q2 2026 from $1.00 in Q2 2025; adjusted EBITDA declined to $461M (29.6% margin) from $522M (32.7% margin) prior year.

  Exhibit 99.1 view on EDGAR →
• medium

  Suspended quarterly earnings press release and conference call due to pending Sun Pharmaceutical merger; furnished non-GAAP metrics separately in 8-K while directing investors to 10-Q for GAAP results.

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →
• medium

  Incurred $11M in transaction costs related to pending Sun Pharmaceutical merger during Q2 2026, excluded from adjusted EBITDA.

  Exhibit 99.1 view on EDGAR →